☆ 4.6 Article

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result

PHARMACEUTICALS (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Ophthalmology

Efficacy and safety of brolucizumab for serous drusenoid pigment epithelium detachment non-responder to bevacizumab and aflibercept

Andrea Saitta et al.

Summary: This case report demonstrates the successful treatment of a woman with drusenoid pigment epithelial detachment (DPED) in age-related macular degeneration using brolucizumab injections. Switching to brolucizumab proved effective in resolving subretinal fluid and collapsing DPED, resulting in improved visual acuity.

EUROPEAN JOURNAL OF OPHTHALMOLOGY (2023)

Add to Collection

Review Ophthalmology

Differentiating drusen and drusenoid deposits subtypes on multimodal imaging and risk of advanced age-related macular degeneration

Yoichi Sakurada et al.

Summary: Drusen, as precursor lesions to advanced age-related macular degeneration (AMD), have different lifecycles and risks depending on their types and sizes. Various imaging modalities can show specific characteristics of drusen types, aiding in assessing the risk of advanced AMD.

JAPANESE JOURNAL OF OPHTHALMOLOGY (2023)

Add to Collection

Article Ophthalmology

Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan

Yohei Hashimoto et al.

Summary: The purpose of this study was to clarify recent trends in the use of intravitreal injections of anti-VEGF in Japan. The study found that the usage of this treatment has increased in recent years, with higher usage rates in men and older age groups. Neovascular age-related macular degeneration was the most common diagnosis for receiving injections, and aflibercept was the most commonly used drug.

JAPANESE JOURNAL OF OPHTHALMOLOGY (2023)

Add to Collection

Article Ophthalmology

Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study

Tomoko Ueda-Consolvo et al.

Summary: This study assessed the effects of switching to brolucizumab from aflibercept on eyes with type 1 macular neovascularization (MNV) and polypoidal choroidal vasculopathy (PCV). The results show that brolucizumab can extend the injection intervals and is correlated with lesion size, treatment frequency, and the number of polyps.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2023)

Add to Collection

Review Ophthalmology

Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies

Caroline R. Baumal et al.

Summary: This review summarized real-world efficacy and safety data on brolucizumab in patients with neovascular age-related macular degeneration (nAMD). The results showed significant improvements in best corrected visual acuity (BCVA) and central subfield thickness (CST) after brolucizumab treatment, as well as prolonged treatment intervals in switch eyes.

ACTA OPHTHALMOLOGICA (2023)

Add to Collection

Article Ophthalmology

KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema

David Brown et al.

Summary: This study compared the efficacy and safety of brolucizumab and aflibercept in patients with diabetic macular edema (DME). The results showed that brolucizumab 6 mg was non-inferior to aflibercept in improving visual acuity and anatomical outcomes, with a favorable benefit/risk profile.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB A Retrospective Case Series of a Single Center Experience

Caroline C. Awh et al.

Summary: Switching to brolucizumab treatment resulted in anatomical improvements in some patients with neovascular age-related macular degeneration, but did not significantly improve visual acuity.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2022)

Add to Collection

Article Ophthalmology

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration Results From the IRIS Registry and Komodo Healthcare Map

Arshad M. Khanani et al.

Summary: A study on patients with neovascular age-related macular degeneration treated with brolucizumab found that the incidence rate of intraocular inflammation and/or retinal vascular occlusion was approximately 2.4%. Patients with a history of these events in the 12 months prior to the first brolucizumab injection had the highest observed risk rate for these events in the early months following treatment.

JAMA OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration

Hikaru Ota et al.

Summary: Switching to brolucizumab for eyes refractory to aflibercept resulted in successful control of exudative changes. However, intraocular inflammation (IOI) and the regulation of treatment interval disrupted the continuation of brolucizumab treatment.

JAPANESE JOURNAL OF OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Arshad M. Khanani et al.

Summary: The 52-week efficacy and safety of brolucizumab and aflibercept in the treatment of neovascular age-related macular degeneration (nAMD) were compared. The study showed that brolucizumab was noninferior to aflibercept in terms of visual acuity improvement and reduction of retinal fluid, but had a higher incidence of intraocular inflammation.

OPHTHALMOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration

Alaa Din Abdin et al.

Summary: The study aimed to evaluate the morphological and functional outcomes of intravitreal brolucizumab treatment for refractory neovascular age-related macular degeneration (nAMD) in the first year. Results showed that brolucizumab could stabilize visual acuity and reduce the number of injections. It also improved anatomical outcomes by reducing subretinal fluid and pigment epithelial detachment. However, adverse events such as intraocular inflammation were observed.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Ophthalmology

Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study - Fifty-Two- Week Outcomes

Debdulal Chakraborty et al.

Summary: The 52-week BRAILLE study demonstrates that brolucizumab is effective and safe in real-world settings for patients with neovascular age-related macular degeneration (nAMD).

CLINICAL OPHTHALMOLOGY (2022)

Add to Collection

Article

A case of intraocular inflammation after intravitreal brolucizumab injection monitored by laser flare-cell photometer

Masaaki Saito et al.

American Journal of Ophthalmology Case Reports (2022)

Add to Collection

Article Ophthalmology

Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration

Yoko Kitajima et al.

Summary: This study evaluated the outcomes of a 6-month follow-up after switching to brolucizumab from aflibercept in Japanese patients with neovascular AMD. The results showed that the switch to brolucizumab effectively maintained visual acuity, reduced central foveal thickness and choroidal thickness, and extended treatment intervals.

JAPANESE JOURNAL OF OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS A Meta-analysis

Nikhil S. Patil et al.

Summary: This meta-analysis investigated the occurrence of intraocular inflammation (IOI) after intravitreal antivascular endothelial growth factor injections in patients with neovascular age-related macular degeneration. The results showed no difference in the risk of severe IOI between different agents, but brolucizumab had a significantly higher incidence of generalized IOI compared to aflibercept.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2022)

Add to Collection

Article

Intravitreal brolucizumab as treatment of early onset radiation retinopathy secondary to plaque brachytherapy for choroidal melanoma

Natacha C. Villegas et al.

American Journal of Ophthalmology Case Reports (2022)

Add to Collection

Review Ophthalmology

Drusen and pachydrusen: the definition, pathogenesis, and clinical significance

Xinyuan Zhang et al.

Summary: The pachychoroid disease spectrum includes various retinal conditions with a focus on Drusen and pachydrusen. While these conditions are related, there are still differences in terms of phenotype, genotype, and pathogenesis that need to be further explored for clinical significance.

EYE (2021)

Add to Collection

Review Ophthalmology

Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration

Ramin Tadayoni et al.

Summary: This article reviews the unique molecular design of brolucizumab, a single-chain antibody fragment specifically designed for intraocular use, which allows for a higher concentration of material per intravitreal injection compared to other anti-VEGF agents. Clinical trials have shown the efficacy of brolucizumab in treating nAMD, with signals of a more durable treatment effect and the ability to be administered every 3 months to maintain disease control. The preclinical and clinical data provide evidence of sustained disease control with longer injection intervals, potentially reducing the treatment burden in nAMD patients.

OPHTHALMOLOGICA (2021)

Add to Collection

Article Medicine, General & Internal

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation

Yumi Shigemoto et al.

Summary: Brolucizumab is effective in treating neovascular AMD, but can cause intraocular inflammation. In this case, combination therapy of brolucizumab and STTA achieved good outcomes after aflibercept failed to control the condition.

MEDICINE (2021)

Add to Collection

Article Ophthalmology

Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy

Keiko Kataoka et al.

Summary: This study describes three Japanese cases of retinal vasculitis following intravitreal brolucizumab injections. Prompt diagnosis and treatment with systemic or local steroids resulted in improvements in vascular sheathing and leakage, with restored visual acuity in all three eyes six weeks after onset.

JAPANESE JOURNAL OF OPHTHALMOLOGY (2021)

Add to Collection

Article Ophthalmology

Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic

Taiichi Hikichi

Summary: Three Japanese patients developed intraocular inflammation after intravitreal injections of brolucizumab to treat neovascular age-related macular degeneration. The onset of inflammation, degree of vitreous opacities, and visual acuity decrease varied among the cases, with improvement observed after injection of triamcinolone acetonide into the sub-Tenon's capsule.

JAPANESE JOURNAL OF OPHTHALMOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration

Ryo G. Mukai et al.

Summary: This study analyzed the risk factors associated with intraocular inflammation following intravitreal brolucizumab injection for AMD. The results showed that older age, female sex, and a history of diabetes were key risk factors for developing intraocular inflammation. Further research is needed to investigate potential risk factors for intraocular inflammation.

PLOS ONE (2021)

Add to Collection

Article Ophthalmology

Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration

Ana Bety Enriquez et al.

Summary: In this analysis of brolucizumab intravitreal injection for neovascular age-related macular degeneration, visual acuity remained stable with a reduction in central subfield thickness. Intraocular inflammation events ranged from mild and self-limited to severe occlusive retinal vasculitis in one eye.

JAMA OPHTHALMOLOGY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD

Lorenzo Ferro Desideri et al.

Summary: Wet age-related macular degeneration (w-AMD) is a leading cause of visual impairment in developed countries. Brolucizumab, a single-chain antibody fragment targeting all isoforms of VEGF-A, has shown longer durability and superior anatomical outcomes in comparison to standard care for w-AMD. It has been approved in Europe, USA, and Japan for w-AMD management.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes

Christof Haensli et al.

Summary: The study aimed to evaluate the effect of switching treatment to brolucizumab in eyes with neovascular age-related macular degeneration with treatment intervals of <= 6 weeks. Results showed improvement in visual performance and longer treatment intervals over 6 months, indicating the potential of brolucizumab to reduce treatment burden in nAMD, despite encountering two cases of intraocular inflammation.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study

Alper Bilgic et al.

Summary: The study aimed to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration in real-world settings. Results showed good anatomical and functional responses to the treatment, with two significant untoward events noted.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study

Alper Bilgic et al.

Summary: The study demonstrates that PRN brolucizumab therapy without a loading dose shows significant efficacy in improving visual acuity for neovascular AMD patients, with no adverse events observed.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

Yoshiko Fukuda et al.

Summary: This study compared the short-term outcomes of aflibercept and brolucizumab in treating polypoidal choroidal vasculopathy, showing similar improvements in visual acuity, morphology, and complete regression of polypoidal lesions. However, brolucizumab was more effective in reducing subfoveal choroidal thickness.

BIOMEDICINES (2021)

Add to Collection

Article Ophthalmology

Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment

Caroline R. Baumal et al.

Summary: This study presents clinical presentations and management recommendations for ocular inflammatory events in neovascular age-related macular degeneration (nAMD) patients treated with brolucizumab. Recommendations include thorough ocular examinations and imaging modalities, prompt cessation of treatment and intensive therapy if diagnosed with inflammatory events, and consideration of individualized locally available standard of care based on clinical outcomes.

OPHTHALMOLOGY RETINA (2021)

Add to Collection

Article Ophthalmology

Association of Choroidal Thickness with Intermediate Age-Related Macular Degeneration in a Japanese Population

Mariko Sasaki et al.

Summary: Choroidal thickness is positively associated with the presence of intermediate AMD and its features in a Japanese population. There is no significant association with early AMD, indicating a potential role of choroidal thickness in the pathology of intermediate AMD in Asians.

OPHTHALMOLOGY RETINA (2021)

Add to Collection

Article Ophthalmology

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Pravin U. Dugel et al.

OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group

Richard F. Spaide et al.

OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

CUTICULAR DRUSEN Risk of Geographic Atrophy and Macular Neovascularization

Yoichi Sakurada et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2020)

Add to Collection

Review Ophthalmology

Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration

Quan Dong Nguyen et al.

OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab

Caroline R. Baumal et al.

OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

Association of CRP levels with ARMS2 and CFH variants in age-related macular degeneration

Taiyo Shijo et al.

INTERNATIONAL OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

HAWK and HARRIER

Pravin U. Dugel et al.

OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

Pseudodrusen pattern and development of late age-related macular degeneration in the fellow eye of the unilateral case

Yoichi Sakurada et al.

JAPANESE JOURNAL OF OPHTHALMOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration

Yoshiko Fukuda et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Article Ophthalmology

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results

Robyn H. Guymer et al.

OPHTHALMOLOGY (2019)

Add to Collection

Article Ophthalmology

Comparison of Ophthalmic Medication Prices Between the United States and Australia

Ravi Parikh et al.

JAMA OPHTHALMOLOGY (2019)

Add to Collection

Review Ophthalmology

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration

Nicolas A. Yannuzzi et al.

CLINICAL OPHTHALMOLOGY (2019)

Add to Collection

Review Ophthalmology

A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific

Ravi Parikh et al.

OPHTHALMOLOGY RETINA (2019)

Add to Collection

Article Ophthalmology

Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Classification of Atrophy Report 3

Srinivas R. Sadda et al.

OPHTHALMOLOGY (2018)

Add to Collection

Article Ophthalmology

Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy

Wataru Kikushima et al.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)

Add to Collection

Article Ophthalmology

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

Masahiro Morimoto et al.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)

Add to Collection

Article Ophthalmology

Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients

Ravi Parikh et al.

OPHTHALMOLOGY (2017)

Add to Collection

Article Ophthalmology

CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY

Yoichi Sakurada et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2017)

Add to Collection

Article Ophthalmology

Treatment Patterns and Health Care Costs for Age-Related Macular Degeneration in Japan An Analysis of National Insurance Claims Data

Atsuki Kume et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration

Hideki Koizumi et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Multidisciplinary Sciences

Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular Degeneration

Yoichi Sakurada et al.

PLOS ONE (2016)

Add to Collection

Article Public, Environmental & Occupational Health

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

Wan Ling Wong et al.

LANCET GLOBAL HEALTH (2014)

Add to Collection

Article Ophthalmology

Subfoveal Choroidal Thickness after Ranibizumab Therapy for Neovascular Age-related Macular Degeneration: 12-Month Results

Taizo Yamazaki et al.

OPHTHALMOLOGY (2012)

Add to Collection

Article Ophthalmology

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

Jeffrey S. Heier et al.

OPHTHALMOLOGY (2012)

Add to Collection

Review Ophthalmology

The Prevalence of Age-Related Macular Degeneration in Asians A Systematic Review and Meta-Analysis

Ryo Kawasaki et al.

OPHTHALMOLOGY (2010)

Add to Collection

Article Ophthalmology

Prevalence and Significance of Subretinal Drusenoid Deposits (Reticular Pseudodrusen) in Age-Related Macular Degeneration

Sandrine A. Zweifel et al.

OPHTHALMOLOGY (2010)

Add to Collection

Article Ophthalmology

Prevalence and causes of low vision and blindness in an urban Malay population - The Singapore Malay Eye Study

Tien Yin Wong et al.

ARCHIVES OF OPHTHALMOLOGY (2008)

Add to Collection

Article Ophthalmology

The natural history and prognosis of neovascular age-related macular degeneration

Tien Wong et al.

OPHTHALMOLOGY (2008)

Add to Collection

Article Medicine, General & Internal

Ranibizumab for neovascular age-related macular degeneration

Philip J. Rosenfeld et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Medicine, General & Internal

Ranibizumab versus verteporfin for neovascular age-related macular degeneration

David M. Brown et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Medicine, General & Internal

Pegaptanib for neovascular age-related macular degeneration

ES Gragoudas et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

Article Ophthalmology

Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy

M Matsuoka et al.

BRITISH JOURNAL OF OPHTHALMOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.